# To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

> **NCT01725126** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 53 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** GSK2890457
- **DRUG:** Metformin
- **DRUG:** Placebo
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT01725126
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-10
- **Primary completion:** 2013-09-12
- **Final completion:** 2013-09-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725126, "To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01725126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*